Journal Mobile Options
Table of Contents
Vol. 36, No. 2, 2007/2008
Issue release date: January 2009
Pathophysiol Haemos Thromb 2007–08;36:53–57
(DOI:10.1159/000173721)

Successful Protein C Concentrate Administration during Initiation of Oral Anticoagulation in Adult Patients with Severe Congenital Protein C Deficiency: Report of Two Cases

Imberti D. · Giorgi Pierfranceschi M.
Thrombosis and Haemostasis Center, Emergency Department, Piacenza Hospital, Piacenza, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Protein C (PC) is a vitamin K-dependent proenzyme with anticoagulant activity, and patients with congenital PC deficiency are at high risk for thrombotic episodes. In patients with PC deficiency, starting treatment with oral anticoagulant drugs is associated with a transient hypercoagulable state and clinically overt thromboembolic complications before reaching a full anticoagulant effect. This report describes a successful supplementation with PC concentrate in two adult patients with moderately severe PC deficiency during the initiation of oral anticoagulation and a course of therapeutic dose of low-molecular-weight heparin for acute venous thromboembolism. Plasma PC levels above 50% were observed in both patients and maintained during the entire supplementation treatment period with PC concentrate until a stable therapeutic anticoagulation level has been reached. These results have been obtained within a short time, thus allowing a safe administration of a loading dose of warfarin. No adverse reactions to the PC concentrate, i.e. skin necrosis and other thromboembolic complications, bleedings or allergic reactions, were observed. We conclude that PC concentrate seems to be effective for the prevention of thromboembolic complications and safe in patients with congenital PC deficiency while initiating oral anticoagulants.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Esmon CT: The protein C anticoagulant pathway. Arterioscler Thromb 1992;12:135–145.
  2. Broekemans AW, Veltkamp JJ, Bertina RM: Congenital protein C deficiency and venous thromboembolism: a study of three Dutch families. N Eng J Med 1983;309:340–346.
  3. Sharon C, Tirindelli MC, Mannucci PM, et al: Homozygous protein C deficiency with moderately severe clinical symptoms. Thromb Res 1986;41:483–488.
  4. Horellou MH, Conrad J, Bertina RM, Samama M: Congenital protein C deficiency and thrombotic disease in nine French families. Br J Med 1984;289:1285–1292.
  5. Tripodi A, Franchi F, Krachclamanikoff A, Mannucci PM: Asymptomatic homozygous protein C deficiency. Acta Haematol 1990;83:152–155.
  6. Melissari E, Kakkar VV: Congenital severe protein C deficiency in adults. Br J Haematol 1989;72:222–228.
  7. Samama M, Horellou MH: Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulant treatment. Thromb Haemost 1984;51:132–138.
  8. Hartman KR, Manco-Johnson M, Rawlings JS, et al: Homozygous protein C deficiency: early treatment with warfarin. Am J Pediatr Hematol Oncol 1989;11:395–401.
  9. Broekmans AW, Bertina RM, Loeliger EA, et al: Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost 1983;49:251.
  10. Marlar RA, Montgomery R, Broekmans AW, et al: Report on diagnosis and treatment of homozygous protein C deficiency of the ICTH-Subcommittee on Protein C and Protein S. Thromb Haemost 1989;61:529–531.
  11. Dreyfus M, Masterson M, David M, et al: Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost 1995;21:371–381.
  12. De Stefano V, Mastrangelo S, Schwarz HP, et al: Replacement with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb Haemost 1993;70:247–249.
  13. Conard J, BauerK, Gruber A, et al: Normalization of markers of coagulation activation with purified protein C concentrate in adults with homozygous protein C deficiency. Blood 1993;82:1159–1164.
  14. Dreyfus M, Magny JF, Bridey F, et al: Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991;325:156–158.

    External Resources

  15. Pezzini A, Del Zotto E, Magoni M, et al: Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke 2003;34:28–33.
  16. Pabinger I, Lechner K, Niesser H, et al: Protein C and coagulation factor level during the initial phase of oral anticoagulant therapy (low dose regimen) in a patient with heterozygous protein C deficiency. Thromb Res 1987;47:705–708.
  17. Mcgehee WG, Klotz TA, Epstein DJ, et al: Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 1984;101:59–60.
  18. Zauber NP, Stark MW: Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med 1986;104:659–660.
  19. Mayer RV, Chisholm M, Hickton MC: Replacement therapy for protein C deficiency using fresh frozen plasma. Br J Haematol 1989;72:475.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50